Atossa Therapeutics (ATOS) Short Interest Ratio & Short Volume

$1.53
+0.01 (+0.66%)
(As of 04/26/2024 ET)

Atossa Therapeutics Short Interest Data

Current Short Volume
12,350,000 shares
Previous Short Volume
10,560,000 shares
Change Vs. Previous Month
+16.95%
Dollar Volume Sold Short
$21.12 million
Short Interest Ratio / Days to Cover
7.6
Last Record Date
April 15, 2024
Outstanding Shares
125,300,000 shares
Percentage of Shares Shorted
9.86%
Today's Trading Volume
898,654 shares
Average Trading Volume
1,395,866 shares
Today's Volume Vs. Average
64%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Atossa Therapeutics ?

Sign up to receive the latest short interest report for Atossa Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

ATOS Short Interest Over Time

ATOS Days to Cover Over Time

ATOS Percentage of Float Shorted Over Time

Atossa Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
4/15/202412,350,000 shares $21.12 million +17.0%N/A7.6 $1.71
3/31/202410,560,000 shares $19.01 million +24.5%N/A7.7 $1.80
3/15/20248,480,000 shares $10.94 million +18.6%N/A9 $1.29
2/29/20247,150,000 shares $6.99 million +1.6%N/A13.6 $0.98
2/15/20247,040,000 shares $7.11 million +2.9%N/A16.8 $1.01
1/31/20246,840,000 shares $5.84 million -2.2%N/A17.4 $0.85
1/15/20246,990,000 shares $6.36 million +9.9%N/A18.4 $0.91
12/31/20236,360,000 shares $5.60 million +1.0%N/A16.7 $0.88
12/15/20236,300,000 shares $4.67 million +1.0%N/A19.3 $0.74
11/30/20236,240,000 shares $4.64 million -2.0%N/A19.3 $0.74
11/15/20236,370,000 shares $4.17 million -4.2%N/A17.4 $0.65
10/31/20236,650,000 shares $4.46 million -5.7%N/A16.4 $0.67
10/15/20237,050,000 shares $4.65 million -2.8%N/A16.3 $0.66
9/30/20237,250,000 shares $5.34 million -8.8%N/A13.1 $0.74
9/15/20237,950,000 shares $6.28 million -3.1%N/A9.7 $0.79
8/31/20238,200,000 shares $6.48 million -1.8%N/A9.6 $0.79
8/15/20238,350,000 shares $7.36 million -1.7%N/A8.6 $0.88
7/31/20238,490,000 shares $9.34 million -2.6%N/A9.1 $1.10
7/15/20238,720,000 shares $10.81 million +12.5%N/A9.5 $1.24
6/30/20237,750,000 shares $9.77 million +6.9%N/A9.8 $1.26
6/15/20237,250,000 shares $6.52 million -3.6%N/A14.4 $0.90
5/31/20237,520,000 shares $6.99 million -3.2%N/A16.1 $0.93
5/15/20237,770,000 shares $5.50 million -3.7%N/A22.4 $0.71
4/30/20238,070,000 shares $5.16 million -3.1%N/A24.9 $0.64
4/15/20238,330,000 shares $6.12 million -1.3%N/A24.4 $0.74
3/31/20238,440,000 shares $6.12 million -1.9%N/A19.4 $0.72
3/15/20238,600,000 shares $5.59 million +0.6%N/A17.1 $0.65
2/28/20238,550,000 shares $6.33 million -2.2%N/A15.5 $0.74
2/15/20238,740,000 shares $6.69 million -0.6%N/A15.9 $0.77
1/31/20238,790,000 shares $7.04 million -3.2%N/A15.6 $0.80
1/15/20239,080,000 shares $7.75 million -1.7%N/A15.5 $0.85
12/30/20229,240,000 shares $4.88 million -3.7%N/A18.1 $0.53
12/15/20229,590,000 shares $5.61 million -4.3%N/A21.2 $0.59
11/30/202210,020,000 shares $7.52 million -4.1%N/A22.4 $0.75
11/15/202210,450,000 shares $8.58 million -0.2%N/A23.7 $0.82
10/31/202210,470,000 shares $10.32 million -1.2%N/A19.5 $0.99
10/15/202210,600,000 shares $8.59 million -5.8%N/A19.2 $0.81
9/30/202211,250,000 shares $9.37 million -1.6%N/A18.9 $0.83
9/15/202211,430,000 shares $10.53 million -2.8%N/A11.8 $0.92
8/31/202211,760,000 shares $10.83 million -1.3%N/A10.1 $0.92
The Next Step of Their Control Is Here … (Ad)

Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.

4 simple steps to protect your privacy and money before it’s too late.

ATOS Short Interest - Frequently Asked Questions

What is Atossa Therapeutics' current short interest?

Short interest is the volume of Atossa Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 12,350,000 shares of ATOS short. Learn More on Atossa Therapeutics' current short interest.

What is a good short interest ratio for Atossa Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ATOS shares currently have a short interest ratio of 8.0. Learn More on Atossa Therapeutics's short interest ratio.

Which institutional investors are shorting Atossa Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Atossa Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Atossa Therapeutics' short interest increasing or decreasing?

Atossa Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 12,350,000 shares, an increase of 17.0% from the previous total of 10,560,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Atossa Therapeutics' short interest compare to its competitors?

Here is how the short interest of companies in the sector of "medical" compare to Atossa Therapeutics: Veru Inc. (7.55%), Alimera Sciences, Inc. (0.21%), Omeros Co. (23.62%), Lifecore Biomedical, Inc. (6.30%), Trevi Therapeutics, Inc. (1.30%), Zevra Therapeutics, Inc. (5.93%), Rigel Pharmaceuticals, Inc. (2.95%), Skye Bioscience, Inc. (0.29%), Inventiva S.A. (0.15%), Adicet Bio, Inc. (9.55%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks.

What does it mean to sell short Atossa Therapeutics stock?

Short selling ATOS is an investing strategy that aims to generate trading profit from Atossa Therapeutics as its price is falling. ATOS shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Atossa Therapeutics?

A short squeeze for Atossa Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ATOS, which in turn drives the price of the stock up even further.

How often is Atossa Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATOS, twice per month. The most recent reporting period available is April, 15 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:ATOS) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners